Principia Biopharma, a Sanofi Company
Clinical trials sponsored by Principia Biopharma, a Sanofi Company, explained in plain language.
A biopharmaceutical company, now a subsidiary of Sanofi, focused on developing treatments for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New pill shows promise for rare bleeding disorder
Disease control CompletedThis study tested an experimental oral drug called rilzabrutinib in 86 adults with relapsed immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The drug aims to block a key immune signal to help raise platelet counts. The …
Phase 2 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo shows promise for rare autoimmune disease
Disease control CompletedThis study tested a new drug called rilzabrutinib combined with steroids in 27 adults with active IgG4-related disease, a rare condition causing inflammation and organ damage. The goal was to see if the combination could prevent disease flares better than steroids alone. Particip…
Phase 2 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New eczema gel shows promise in early trial
Symptom relief CompletedThis study tested a new topical gel called PRN473 (SAR444727) in 39 adults with mild to moderate atopic dermatitis (eczema). Each participant had two similar patches of eczema treated: one with the study gel and one with a placebo gel, without knowing which was which. The main go…
Phase 2 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Symptom relief
Last updated Jun 26, 2026 16:13 UTC
-
Healthy volunteers help Fine-Tune rilzabrutinib dosing
Knowledge-focused CompletedThis early-stage study tested how taking rilzabrutinib with or without food, and in different pill forms, changes the drug levels in the body. Twenty-four healthy volunteers each received a single dose. The goal was to find the best way to give the drug in future trials, not to t…
Phase 1 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC